{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:57:44Z","timestamp":1772161064038,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR055989"],"award-info":[{"award-number":["K24 AR055989"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.semarthrit.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T14:45:13Z","timestamp":1409150713000},"page":"399-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs"],"prefix":"10.1016","volume":"44","author":[{"given":"Maria D.","family":"Mjaavatten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Radner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Shadick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Frits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine K.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2014.08.003_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib3","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.20248","article-title":"Measuring quality in arthritis care: methods for developing the Arthritis Foundation\u05f3s quality indicator set","volume":"51","author":"MacLean","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/acr.22084","article-title":"Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review","volume":"65","author":"Schmajuk","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib8","first-page":"S13","article-title":"Increases in use of methotrexate since the 1980s","volume":"28","author":"Sokka","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/ker356","article-title":"Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA","volume":"51","author":"Lie","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/keq263","article-title":"Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women\u05f3s Hospital Rheumatoid Arthritis Sequential Study","volume":"50","author":"Iannaccone","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.22549","article-title":"Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries","volume":"57","author":"Solomon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib13","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/art.10817","article-title":"Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2014.08.003_bib16","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10067-010-1636-7","article-title":"Observational studies: a valuable source for data on the true value of RA therapies","volume":"30","author":"van Vollenhoven","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","article-title":"Biologic discontinuation studies: a systematic review of methods","volume":"73","author":"Yoshida","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/ard.2003.016808","article-title":"Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project)","volume":"63","author":"Kastbom","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1358\/dnp.2009.22.9.1437962","article-title":"The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?","volume":"22","author":"Lopez-Longo","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.berh.2007.05.007","article-title":"Extra-articular manifestations and complications of rheumatoid arthritis","volume":"21","author":"Young","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.08.003_bib22","unstructured":"Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits MF, Iannaccone CK, et al., Inconsistent treatment with disease-modifying anti-rheumatic drugs: a longitudinal data analysis. J Rheumatol (in press)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214001851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214001851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:56:20Z","timestamp":1758732980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017214001851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0049017214001851"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.08.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}